Douglas A. Levine

机构：Merck & Co., Inc., Rahway, NJ, USA (United States), NYU Langone Health · ORCID：0000-0003-1038-8232

发表论文 830 篇 · 总被引 125813 次 · h-index 130

代表论文

• Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer (2025 · Cell · 被引 33)
• Efficacy and safety of the DLL3 T-cell engager gocatamig in participants (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN). (2026 · Journal of Clinical Oncology · 被引 2)
• Patient-Centered Approach to Surgical Prevention of Ovarian Cancer (2026 · JAMA Network Open · 被引 1)
• Author Correction: Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma (2026 · Nature Communications)
• Figure S4 from PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma (2025)
• Table S2 from PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma (2025)